For two companies the FDA PRO Guidance leads to similar but different measures

A case study in psoriasis

Mordin, M., Brown, T., McLeod, L., DeMuro, C., & Gnanasakthy, A. (2015). For two companies the FDA PRO Guidance leads to similar but different measures: A case study in psoriasis. Value in Health, 18(3), A111-A111. https://doi.org/10.1016/j.jval.2015.03.653

Abstract

The objective of this research is to evaluate whether the 2009 FDA PRO Guidance leads to development of similar measures when followed by different researchers in the same disease. Psoriasis was selected as a case study, because two companies recently published patient-reported outcome measures to assess the severity of psoriasis-related symptoms: the Psoriasis Symptom Inventory (PSI) and the Psoriasis Symptom Diary (PSD).

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Far-right and Jihadi terrorism within the United States
Article

Internalizing and externalizing subtypes of alcohol misuse and their relation to drinking motives
Article

Does the relationship between alcohol retail environment and alcohol outcomes vary by depressive symptoms? Findings from a US Survey of Black, Hispanic and White drinkers
Article

What's in a name? A data-driven method to identify optimal psychotherapy classifications to advance treatment research on co-occurring PTSD and substance use disorders